期刊
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
卷 13, 期 4, 页码 333-344出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/1744666X.2017.1244004
关键词
Spondyloarthritis; psoriasis; inflammatory bowel diseases; serum; biomarkers
类别
资金
- Janssen
- Netherlands Organization for Scientific Research (NWO)
- Dutch Arthritis Foundation (Reumafonds)
- European Research Council (ERC)
- ReumaFonds [LLP-2] Funding Source: researchfish
Introduction: Early diagnosis, monitoring of disease activity, prediction of treatment response, and structural outcome remain major challenges in spondyloarthritis (SpA). Biomarkers could play a role in addressing these challenges, but in SpA there is a lack of suitable biomarkers.Areas covered: As SpA is clinically and pathophysiologically closely related to psoriasis and inflammatory bowel disease (IBD), we reviewed in literature, the value of serum biomarkers in these conditions with the aim to find potential candidates for assessing SpA.Expert commentary: Candidates of interest were antimicrobial peptides, including serum human beta defensin-2 (hBD-2) and lipocalin-2 (LCN-2), and class-1 MHC molecule beta2-microglobulin. Since these biomarkers are relevant in psoriasis and/or IBD from a pathophysiological point of view, and may play a role in the pathogenesis of SpA, we recommend further exploration of their value as biomarker in the diagnosis and prognosis of SpA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据